Palatin Technologies Inc (PTN) Stock Price & Analysis
Palatin Technologies Inc (PTN) rose 0.57% to USD 14.2 as of June 10, 2026 at 07:32 UTC, according to Nexqual real-time market data.
PTN last closed at USD 14.12; the session ranged USD 14–14.8 on volume of 4,426 shares. Market capitalization is $25.27M, with a 52-week range of USD 4.5–31 (NCM). Source: Nexqual, June 10, 2026 at 07:32 UTC.
Key Statistics (as of June 10, 2026 at 07:32 UTC)
| Price | USD 14.2 |
|---|---|
| Change | ▲ 0.57% (up) |
| Previous Close | USD 14.12 |
| Open | USD 14.04 |
| Day Range | USD 14 – 14.8 |
| 52-Week Range | USD 4.5 – 31 |
| Volume | 4,426 shares |
| Market Cap | $25.27M |
| Exchange | NCM |
Technical Analysis (PTN)
Nexqual's technical model rates PTN "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:32 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 35.41 (neutral) |
| vs SMA50 | Below (USD 17.95) |
| MACD | -1.29 (negative) |
Analyst Ratings (PTN)
Wall Street analysts rate PTN "None" based on 3 analysts, with a mean price target of USD 53.5 (range USD 47.5–60), per Nexqual as of June 10, 2026 at 07:32 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 53.5 |
| High Target | USD 60 |
| Low Target | USD 47.5 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (PTN)
| EPS Estimate | USD -1.13 |
|---|---|
| Revenue Estimate | $833,330 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.37 vs est -0.82 ▲ beat |
| 2025-12-31 | USD -2.86 vs est -1.47 ▼ miss |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financials & Fundamentals (PTN)
| Total Revenue | $12.88M |
|---|---|
| Gross Margin | +4.28% |
| Operating Margin | -40.33% |
| Profit Margin | -48.50% |
| ROE | -297.24% |
| Debt / Equity | 2.71 |
| Current Ratio | 5.04 |
| Total Cash | $10.16M |
| Total Debt | $286,662 |
| Free Cash Flow | $-13.67M |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financial Health Score (PTN)
Nexqual rates Palatin Technologies Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:32 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$15M |
| Efficiency | Critical — ROE -297%, ROA -65.3% |
Ownership (PTN)
| Insider Ownership | +1.08% |
|---|---|
| Institutional Ownership | +55.58% |
| Shares Outstanding | 1.78M |
| Float | 1.38M |
| Short % of Float | +10.33% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Leadership (PTN)
Palatin Technologies Inc is led by Carl Spana (age 63), Co-Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 07:32 UTC.
| Co-Founder, President, CEO & Director | Carl Spana (age 63) |
|---|---|
| CFO, COO, Executive VP, Treasurer & Secretary | Stephen T. Wills CPA, MST (age 68) |
| Vice President of Investor Relations | Burns McClellan |
| Senior Vice President of Business Development | James E. Hattersley B.A., M.S. (age 65) |
| Senior Vice President of Preclinical Development | John Dodd |
Major Backers & Investors (PTN)
Notable institutional backers of Palatin Technologies Inc include Driehaus Capital Management, LLC, Janus Henderson Group PLC, Logos Global Management LP, according to Nexqual as of June 10, 2026 at 07:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Driehaus Capital Management, LLC | 17.13% |
| Janus Henderson Group PLC | 14.38% |
| Logos Global Management LP | 14.38% |
| RA Capital Management, L.P. | 7.19% |
| Perceptive Advisors Llc | 6.36% |
| Balyasny Asset Management LP | 4.23% |
| Superstring Capital Management LP | 3.7% |
| Morgan Stanley | 2.8% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.9% |
| Geode Capital | 1.9% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
From Palatin Technologies Inc's Latest SEC 10-K Filing (filed 2025-09-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
- It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.
- The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBIO | Mustang Bio, Inc. | USD 0.74 | ▲ 10.75% |
| JAGX | Jaguar Health, Inc. | USD 2.82 | ▲ 0.71% |
| OGEN | Oragenics Inc. | USD 0.6 | ▲ 1.69% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 11.46 | ▲ 3.52% |
| ATOS | Atossa Therapeutics, Inc. | USD 4.41 | ▼ 1.34% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:32 UTC. This page is informational and not investment advice.